Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors

Mathieu Artifoni, Gwenvael Danic, Giovanni Gautier, Pascal Gicquel, David Boutoille, François Raffi, Antoine Néel, Raphaël Lecomte, Mathieu Artifoni, Gwenvael Danic, Giovanni Gautier, Pascal Gicquel, David Boutoille, François Raffi, Antoine Néel, Raphaël Lecomte

Abstract

Coagulopathy in COVID-19 is a burning issue and strategies to prevent thromboembolic events are debated and highly heterogeneous. The objective was to determine incidence and risk factors of venous thromboembolism (VTE) in COVID-19 inpatients receiving thromboprophylaxis. In this retrospective French cohort study, patients hospitalized in medical wards non-ICU with confirmed COVID-19 and adequate thromboprophylaxis were included. A systematic low limb venous duplex ultrasonography was performed at hospital discharge or earlier if deep venous thrombosis (DVT) was clinically suspected. Chest angio-CT scan was performed when pulmonary embolism (PE) was suspected. Of 71 patients, 16 developed VTE (22.5%) and 7 PE (10%) despite adequate thromboprophylaxis. D-dimers at baseline were significantly higher in patients with DVT (p < 0.001). Demographics, comorbidities, disease manifestations, severity score, and other biological parameters, including inflammatory markers, were similar in patients with and without VTE. The negative predictive value of a baseline D-dimer level < 1.0 µg/ml was 90% for VTE and 98% for PE. The positive predictive value for VTE was 44% and 67% for D-dimer level ≥ 1.0 µg/ml and ≥ 3 µg/ml, respectively. The association between D-dimer level and VTE risk increased by taking into account the latest available D-dimer level prior to venous duplex ultrasonography for the patients with monitoring of D-dimer. Despite thromboprophylaxis, the risk of VTE is high in COVID-19 non-ICU inpatients. Increased D-dimer concentrations of more than 1.0 μg/ml predict the risk of venous thromboembolism. D-dimer level-guided aggressive thromboprophylaxis regimens using higher doses of heparin should be evaluated in prospective studies.

Keywords: COVID-19; D-dimer; Pulmonary embolism; Venous thromboembolism.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Fig. 1
Fig. 1
correlation between D-dimer levels and venous thromboembolic events in the 65 COVID-19 patients who had a D-dimer level measurement on admission. (a, top left) Baseline (admission) D-dimer levels according to thromboembolism events. Stars represent pulmonary embolism. (b, top right) Risk of deep venous thrombosis and pulmonary embolism according to baseline D-dimer levels. (c, bottom, left) D-dimer levels kinetics between baseline and the latest value before the venous duplex ultrasonography in the 15 patients with D-dimer levels monitoring. 7 patients with no VTE, median [IQR] admission D-dimer: 0.62 [0.41–1.34], median [IQR] last-value: 0.66 [0.61–0.89]; 8 patients with VTE, median [IQR] admission D-dimer: 2.01 [0.62–4.30], median [IQR] last-value: 4.75 [2.98–6.42] (d, bottom, right) Risk of deep venous thrombosis and pulmonary embolism according to the latest D-dimer levels. VTE venous thromboembolic events, DVT deep venous thrombosis, PE pulmonary embolism. **p < 0.01

References

    1. Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med. 2020 doi: 10.1056/NEJMoa2002032.
    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet Lond Engl. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet Lond Engl. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
    1. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost JTH. 2020;18:844–847. doi: 10.1111/jth.14768.
    1. Grillet F, Behr J, Calame P, et al. Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography. Radiology. 2020 doi: 10.1148/radiol.2020201544.
    1. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost JTH. 2020 doi: 10.1111/jth.14817.
    1. Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis. 2020 doi: 10.1007/s11239-020-02105-8.
    1. Spyropoulos AC, Ageno W, Barnathan ES. Hospital-based use of thromboprophylaxis in patients with COVID-19. Lancet Lond Engl. 2020 doi: 10.1016/S0140-6736(20)30926-0.
    1. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020 doi: 10.1111/jth.14810.
    1. Bernheim A, Mei X, Huang M, et al. Chest CT findings in Coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology. 2020 doi: 10.1148/radiol.2020200463.
    1. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341:793–800. doi: 10.1056/NEJM199909093411103.
    1. Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost JTH. 2020 doi: 10.1111/jth.14830.
    1. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020 doi: 10.1016/j.thromres.2020.04.013.
    1. Poterucha TJ, Libby P, Goldhaber SZ. More than an anticoagulant: do heparins have direct anti-inflammatory effects? Thromb Haemost. 2017;117:437–444. doi: 10.1160/TH16-08-0620.
    1. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet Lond Engl. 2020 doi: 10.1016/S0140-6736(20)30937-5.

Source: PubMed

3
S'abonner